LOGIN  |  REGISTER
Recursion

Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update

March 14, 2025 | Last Trade: US$3.00 0.00 0.00

MORRISTOWN, N.J., March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com.

About Aadi Bioscience 

Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers.

Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Recursion

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page